Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality
Brooks Laboratories Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 11:17 pm
Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality The Board of Brooks Laboratories approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality on 14th Oct'26. The transferred unit contributed Rs. 8,287.26 lakhs in FY26, representing 96.66% of total revenue. Shareholders will receive 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories, with identical shareholding mirror (52.62% promoter, 47.38% public). Post-demerger, Abridge Speciality will list on BSE and NSE and be renamed Brooks Laboratories, while the residual trading business will be renamed Xuri Lifesciences. Listing is targeted within ~16 months.
Original exchange filing (PDF)
More announcements from Brooks Laboratories Ltd
- Intimation of upgrade in Credit Rating 路 12 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 07 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 07 Nov 2026
- Brooks Laboratories Limited has submitted to the Exchange, the financial results for the quarter and half year ended September 30, 2026. 路 07 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 07 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 07 Nov 2026
- Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the Unaudited Standalone .... 路 07 Nov 2026
- Brooks Laboratories Limited has informed the BSE that the meeting of Board of Directors of the Company is scheduled on 07/11/2026, inter alia, to consider and approve take on records the .... 路 03 Nov 2026
